Drug Search Results
More Filters [+]

Lonafarnib

Alternative Names: lonafarnib, sarasar, sch 66336, sch66336, zokinvy
Latest Update: 2024-05-03
Latest Update Note: News Article

Product Description

Lonafarnib is an oral, small molecule inhibitor of farnesyltransferase that is used to treat Hutchison-Gilford progeria syndrome and is under investigation as therapy of chronic hepatitis D.  (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Lonafarnib)

Mechanisms of Action: FT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Belgium | Croatia | Czech | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Poland | Portugal | Slovakia | Sweden | United States

Approved Indications: Progeria

Known Adverse Events: Hypertension | Abdominal Pain | Headache | Pain Unspecified | Musculoskeletal Pain | Diarrhea

Company: Eiger BioPharmaceuticals
Company Location: PALO ALTO CA 94306
Company CEO: David A. Cory
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lonafarnib

Countries in Clinic: Belgium, Bulgaria, Canada, France, Germany, Greece, Israel, Italy, Moldova, Mongolia, New Zealand, Pakistan, Romania, Russia, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Hepatitis A|Hepatitis D|Hepatitis D, Chronic|Hepatocellular Carcinoma|Liver Cirrhosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LOWR6

P3

Active, not recruiting

Hepatitis D, Chronic|Hepatitis A

2024-12-31

D-LIVR

P3

Active, not recruiting

Hepatocellular Carcinoma|Liver Cirrhosis

2023-01-24

D-LIVR

P3

Completed

Hepatitis D

2022-10-06

46%

Recent News Events